Synlogic and Mirna Therapeutics will host a conference call to discuss the proposed transaction as well as Synlogic’s platform and pipeline assets on  May 16, 2017 at 8:30 AM ET . The live webcast can be accessed through the information below....

– Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines – – Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors – – Combined Company Well-Capitalized with Approximately...

Cambridge, Mass (BUSINESS WIRE).  March 22 nd , 2017.  Synlogic™ Inc. today announced that the company will present preclinical data on two rare metabolic disease programs from its Synthetic Biotics™ platform at the American College of Medical Genetics and Genomics Annual Meeting from...

Experienced biotechnology leader, Sam Truex, joins Synlogic’s leadership team CAMBRIDGE, Mass., December 15, 2016 – CAMBRIDGE, Mass. – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced...

First Live  E. Coli  Nissle Bacterium Modified to Assimilate Ammonia Potential Treatment of Urea Cycle Disorders and Other Forms of Hyperammonemia CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

Company Appoints Seasoned Biotech Executives to Lead Finance, Clinical, Translational and Manufacturing Functions September 12, 2016 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

The Company Has Developed The First Live  E. Coli  Nissle Bacterium Modified To Assimilate Ammonia For The Potential Treatment Of Urea Cycle Disorders CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

CAMBRIDGE, Mass., – March 23, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr....

Additional funding to accelerate the two lead Urea Cycle Disorder and Phenylketonuria pipeline programs to the clinic and expand the Synthetic Biotics platform CAMBRIDGE, Mass., – February 17, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...

Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease  CAMBRIDGE, Mass., – February 10, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and the...

CAMBRIDGE, Mass., – January 5, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced that J.C. Gutiérrez-Ramos, Ph.D., Chief Executive Officer of Synlogic will present at a...

Bharatt Chowrira, Ph.D., J.D., appointed as Synlogic’s President bringing industry expertise in corporate development, strategy, intellectual property and financing Two proprietary rare disease programs being advanced into clinical development with accelerated financing An R&D collaboration...